Invasive Fungal Infections Global Market Report 2024

The invasive fungal infections market size has grown strongly in recent years. It will grow from $7.21 billion in 2023 to $7.58 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to the global spread of infections, hematopoietic stem cell transplants, an aging population, hospital-acquired infections, and environmental factors.

The invasive fungal infections market size is expected to see steady growth in the next few years. It will grow to $9.08 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to global health preparedness, public health education, the development of novel antifungal agents, the impact of climate change, and multidisciplinary approaches. Major trends in the forecast period include advancements in diagnostic technologies, tailored therapeutic approaches, patient-centric care, combination antifungal therapies, and collaborations for drug development.

The projected increase in the population afflicted by Human Immunodeficiency Virus (HIV) is anticipated to propel the expansion of the invasive fungal infection market in the coming years. HIV is a virus that compromises the immune system's ability to combat diseases and infections. As the number of individuals with compromised immune systems, including those affected by HIV or AIDS, rises, susceptibility to invasive fungal infections escalates. This surge creates opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS) in July 2023, the global population living with HIV increased to 39 million in 2022, marking a 3.17% rise from 37.7 million in 2020. Additionally, approximately 1.3 million new HIV infections were reported in 2022. Hence, the anticipated rise in the population affected by HIV is expected to drive the growth of the invasive fungal infection market.

The mounting number of cancer patients is forecasted to fuel the expansion of the invasive fungal infections market in the future. Invasive fungal infections (IFIs) pose severe and potentially life-threatening complications for cancer patients, particularly those with weakened immune systems. The growing population of cancer survivors is a significant factor contributing to the increased risk of IFIs among these individuals. As reported by the National Cancer Institute in November 2022, it is projected that by 2040, there will be approximately 26.0 million cancer survivors. Furthermore, the number of individuals who have survived five or more years after a cancer diagnosis is expected to surge by nearly 30%, reaching 16.3 million over the subsequent decade. Consequently, the escalating number of cancer patients and survivors stands as a driving force behind the growth of the invasive fungal infections market.

The emergence of drug-resistant fungal strains represents a notable challenge that may impede the growth of the invasive fungal infection market during the forecast period. The appearance of these resistant strains poses a substantial hurdle in the treatment of invasive fungal infections. With evolving defenses that enable survival against modern medicines, these strains compromise the efficacy of antifungal drugs, complicating the treatment of patients affected by such infections. For instance, as reported by CIDRAP (Center for Infectious Disease Research and Policy) in March 2023, there was a concerning 95% increase in Candida auris followed by a 59% rise in 2020. This spike in drug-resistant fungal strains highlights a significant obstacle and contributes to hindering the growth trajectory of the invasive fungal infection market.

Prominent companies operating within the invasive fungal infection market are dedicated to developing advanced antifungal drugs, such as Posaconazole, to meet the escalating demand for more effective and innovative treatments for fungal infections, aiming to attain a competitive advantage in the market. Antifungal medications such as Posaconazole are specifically designed to combat fungal infections by either inhibiting their growth or eradicating the fungi responsible for the infection. For instance, in June 2021, Cadila Pharmaceuticals Ltd., a renowned pharmaceutical company based in India, introduced Posaconazole, a novel triazole antifungal drug. This drug demonstrates efficacy against various invasive fungal diseases and is recommended as a secondary treatment for mucormycosis (black fungus). Approved for preventing aspergillus and candida infections in immunocompromised patients, as well as for treating oropharyngeal candidiasis (OPC), Posaconazole represents an innovative addition to the arsenal of treatments available for these fungal infections.

In April 2021, Pfizer Inc., a prominent US-based pharmaceutical company, completed the acquisition of Amplyx Pharmaceuticals, Inc. for an undisclosed sum. This strategic acquisition marks Pfizer's expansion in the realm of infectious diseases and anti-infectives by incorporating a promising Phase 2 antifungal candidate, Fosmanogepix (APX001), specifically developed for the treatment of invasive fungal infections. Amplyx Pharmaceuticals, Inc., a US-based pharmaceutical company renowned for its focus on pioneering therapies targeting life-threatening diseases, notably invasive fungal infections, provided Pfizer with this innovative antifungal candidate as part of the acquisition.

Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMérieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB.

North America was the largest region in the invasive fungal infections market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the invasive fungal infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The invasive fungal infections market consists of revenues earned by entities by providing services such as diagnostic testing, clinical research and development, educational programs, and awareness campaign services. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive fungal infections market also includes sales of azoles, allylamines, and morpholines, which are used in treating invasive fungal infections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of invasive fungal infections encompass candidemia and invasive candidiasis, intraabdominal candidiasis, cryptococcal meningitis, esophageal candidiasis, histoplasmosis acute pulmonary, and others. Candidemia and invasive candidiasis, for instance, are infections caused by Candida fungus that can affect various parts of the body, including the blood, heart, brain, eyes, bones, or other organs. Treatment involves the use of different drug types, such as polyenes, triazoles, echinocandins, flucytosine, and others, and is administered by various end-users, including hospitals, homecare, specialty clinics, and others.

The invasive fungal infections market research report is one of a series of new reports that provides invasive fungal infections market statistics, including invasive fungal infections industry global market size, regional shares, competitors with a invasive fungal infections market share, detailed invasive fungal infections market segments, market trends and opportunities, and any further data you may need to thrive in the invasive fungal infections industry. This invasive fungal infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.